alfuzosin

アルフゾシン

関

alfuzosin hydrochloride

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/06/19 15:52:50」(JST)

wiki en

[Wiki en表示]

Alfuzosin

Clinical data
Pronunciation	/ælˈfjuːzoʊsɪn/ al-FEW-zoh-sin
Trade names	Uroxatral, others
AHFS/Drugs.com	Monograph
MedlinePlus	a64002
Pregnancy category	AU: B2 US: B (No risk in non-human studies)
Routes of administration	By mouth (tablets)
ATC code	G04CA01 (WHO)
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	49%
Protein binding	82–90%
Metabolism	Liver (CYP3A4-mediated)
Biological half-life	10 hours
Excretion	Feces (69%) and Urine (24%)
Identifiers
IUPAC name N-[3-[(4-Amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide
CAS Number	81403-80-7 Y
PubChem CID	2092
IUPHAR/BPS	7109
DrugBank	DB00346 Y
ChemSpider	2008 Y
UNII	90347YTW5F
KEGG	D07124 Y
ChEBI	CHEBI:51141 Y
ChEMBL	CHEMBL709 Y
ECHA InfoCard	100.108.671
Chemical and physical data
Formula	C19H27N5O4
Molar mass	389.449 g/mol
3D model (Jmol)	Interactive image
SMILES O=C(NCCCN(c2nc1cc(OC)c(OC)cc1c(n2)N)C)C3OCCC3
InChI InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23) Y Key:WNMJYKCGWZFFKR-UHFFFAOYSA-N Y
(verify)

Alfuzosin (INN, provided as the hydrochloride salt) is a pharmaceutical drug of the α₁ blocker class. As an antagonist of the α₁ adrenergic receptor, it works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. It is thus used to treat benign prostatic hyperplasia (BPH).

Alfuzosin is marketed in the United States by Sanofi Aventis under the brand name Uroxatral and elsewhere under the tradenames Xat, Xatral, Prostetrol and Alfural. Alfuzosin was approved by the U.S. FDA for treatment of BPH in June 2003.

Side effects

The most common side effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, fatigue, and abdominal disturbances.

Contraindications

Alfuzosin should be used with caution in patients with severe renal insufficiency, and should not be prescribed to patients with a known history of QT prolongation who are taking medications known to prolong the QT interval.

External links

• Uroxatral (alfuzosin HCl) Extended-Release Tablets Prescribing Information
• Alfuzosin (General information from the NIH)

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. 前立腺肥大症の内科的治療 medical treatment of benign prostatic hyperplasia
• 2. 尿管ステントの留置およびマネージメント placement and management of indwelling ureteral stents
• 3. 男性における下部尿路症状 lower urinary tract symptoms in men
• 4. 糖尿病症例解説20：長期に渡る2型糖尿病、起立性低血圧および再発性失神を有する76歳男性 interactive diabetes case 20 a 76 year old man with long standing type 2 diabetes orthostatic hypotension and recurrent syncope
• 5. 急性尿閉 acute urinary retention

English Journal

• An efficient spectrofluorimetric method adopts doxazosin, terazosin and alfuzosin coupling with orthophthalaldehyde: Application in human plasma.

• Omar MA1, Mohamed AI2, Derayea SM3, Hammad MA4, Mohamed AA1.
• Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.Spectrochim Acta A Mol Biomol Spectrosc.2018 Apr 15;195:215-222. doi: 10.1016/j.saa.2018.01.077. Epub 2018 Feb 1.
• PMID 29414581

• Efficacy and safety of alpha blockers in medical expulsive therapy for ureteral stones: a mixed treatment network meta-analysis and trial sequential analysis of randomized controlled clinical trials.

• Sridharan K1, Sivaramakrishnan G2.
• Expert review of clinical pharmacology.Expert Rev Clin Pharmacol.2018 Mar;11(3):291-307. doi: 10.1080/17512433.2018.1424537. Epub 2018 Jan 19.
• PMID 29334287

• Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia.

• Duan Y1,2, Grady JJ1,2, Albertsen PC3, Helen Wu Z2,4.
• Pharmacoepidemiology and drug safety.Pharmacoepidemiol Drug Saf.2018 Jan 9. doi: 10.1002/pds.4361. [Epub ahead of print]
• PMID 29316005

Japanese Journal

• Tamsulosin Potently and Selectively Antagonizes Human Recombinant α₁A/₁D-Adrenoceptors : Slow Dissociation from the α₁A-Adrenoceptor May Account for Selectivity for α₁A-Adrenoceptor over α₁B-Adrenoceptor Subtype

• Sato Shuichi,Hatanaka Toshiki,Yuyama Hironori [他],Ukai Masashi,Noguchi Yukiko,Ohtake Akiyoshi,Taguchi Katsunari,Sasamata Masao,Miyata Keiji
• Biological and Pharmaceutical Bulletin 35(1), 72-77, 2012
• … We determined the binding affinity of tamsulosin, a selective α1-adrenoceptor antagonist, for human α1-adrenoceptor subtypes in comparison with those of other α1-adrenoceptor antagonists including silodosin, prazosin, 5-methylurapidil, terazosin, alfuzosin, nafopidil, urapidil and BMY7378. …
• NAID 130001872345

• Medical expulsive therapy using alfuzosin for patient presenting with ureteral stone less than 10mm : A prospective randomized controlled trial

• CHAU Lysander Hin,TAI Dominic Chi Kin,FUNG Berry Tat Chow,LI James Cheuk Man,FAN Chi Wai,LI Michael Ka Wah
• International journal of urology 18(7), 510-514, 2011-07-01
• NAID 10030719675

• The Forefront for Novel Therapeutic Agents Based on the Pathophysiology of Lower Urinary Tract Dysfunction : α-Blockers in the Treatment of Male Voiding Dysfunction-How Do They Work and Why Do They Differ in Tolerability?

• Michel Martin C.
• Journal of pharmacological sciences 112(2), 151-157, 2010-02-20
• NAID 10029888675

Related Pictures

---

★リンクテーブル★

リンク元	「アルフゾシン」
拡張検索	「alfuzosin hydrochloride」

「アルフゾシン」

　　[★]

英

alfuzosin、alfuzosin hydrochloride

関

塩酸アルフゾシン

「alfuzosin hydrochloride」

　　[★]

• 塩酸アルフゾシン

関

alfuzosin